Ligand Pharmaceuticals

Recent news

• Rating change
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345
  Market Newswire · 2026/8/7
• Rating change
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $345
  Market Newswire · 2026/8/10
• Rating change
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388
  Market Newswire · 2026/7/22
• Rating change
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $388
  Market Newswire · 2026/7/9
• A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $388 to $397
  Market Newswire · 2026/9/23
• Rating change
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $266
  Market Newswire · 2026/5/28
• Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $397
  Market Newswire · 2026/9/24
• Rating change
  Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335
  Market Newswire · 2026/7/16
• Rating change
  A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370
  Market Newswire · 2026/8/8
• Rating change
  Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $326
  Market Newswire · 2026/8/3
• Rating change
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $266
  Market Newswire · 2026/6/2
• Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345
  Market Newswire · 2026/9/25
• H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358
  Market Newswire · 2026/9/24
• Rating change
  Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $332
  Market Newswire · 2026/7/8
• Rating change
  Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $387
  Market Newswire · 2026/7/22
• Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
  Market Newswire · 2026/9/24
• Rating change
  H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $358
  Market Newswire · 2026/8/7
• Rating change
  Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $332
  Market Newswire · 2026/8/14
• Rating change
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $340
  Market Newswire · 2026/7/15
• Rating change
  Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390
  Market Newswire · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.